Onkologie, Hämatologie - Daten und Informationen

Literatur zu Kapitel 8.5: Immuntherapie der AML

Autor/en: M. Stelljes, L. Uharek
Letzte Änderung: 01.07.2008
  • Appelbaum FR.
    Antibody-targeted therapy for myeloid leukemia.
    Sem Hematol 1999;36(Suppl6):2-8.

  • Blaise D et al.
    The use of a sequential high dose recombinant interleukin 2 regimen after autologous bone marrow transplantation does not improve the disease free survival of patients with acute leukemia transplanted in first complete remission.
    Leuk Lymphoma 1997;25(5-6):469-478.

  • Galea-Lauri J.
    Immunological weapons against acute myeloid leukaemia.
    Immunology 2002;107(1):20-27.

  • Goulmy E.
    Minor histocompatibility antigens: from transplantation problems to therapy of cancer.
    Hum Immunol 2006;67(6):433-438.

  • Greiner J, Dohner H, Schmitt M.
    Cancer vaccines for patients with acute myeloid leukemia - defintion of leukemia-associated antigens and current clinical protocols targeting these antigens.
    Haematologica 2006;91(12):1653-1661.

  • Kolb HJ et al.
    Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.
    Blood 1990;76(12):2462-2465.

  • Kolb HJ et al.
    Graft-versus-leukemia reactions in allogeneic chimeras.
    Blood 2004;103(3):767-776.

  • Larson RA et al.
    Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence.
    Cancer 2005;104(7):1442-1452.

  • Mailander V et al.
    Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicity.
    Leukemia 2004;18(1):165-166.

  • Meloni G et al.
    Interleukin-2 may induce prolonged remissions in advanced acute myelogenous leukemia.
    Blood 1994;84(7):2158-2163.

  • Miller JS et al.
    Successful adoptive transfer and in vivo expansion of human haploidentical NK cells in patients with cancer.
    Blood 2005;105(8):3051-3057.

  • Qazilbash MH et al.
    PR1 vaccine after hematopoietic stem cell transplantation.
    Biol Blood Marrow Transplant 2006;12(2):16.

  • Rusakiewicz S, Molldrem JJ.
    Immunotherapeutic peptide vaccination with leukemia-associated antigens.
    Curr Opin Immunol 2006;18(5):599-604.

  • Schmid C et al.
    Low-dose ARAC, donor cells, and GM-CSF for treatment of recurrent acute myeloid leukemia after allogeneic stem cell transplantation.
    Leukemia 2004;18(8):1430-1433.

  • Taksin AL et al.
    High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: A prospective study of the alfa group.
    Leukemia 2007;21(1):66-71.

  • Gleissner B et al.
    Gemtuzumab ozogamicin (mylotarg) for the treatment of acute myeloid leukemia--ongoing trials.
    Onkologie 2007;30(12):657-62.

  • Thomas X et al.
    Effect of priming with granulocyte-macrophage colony-stimulating factor in younger adults with newly diagnosed acute myeloid leukemia: a trial by the Acute Leukemia French Association (ALFA) Group.
    Leukemia 2007;21(3):453-461.

  • van Bergen CA et al.
    Multiple myeloma-reactive T cells recognize an activation-induced minor histocompatibility antigen encoded by the ATP-dependent interferon-responsive (ADIR) gene.
    Blood 2007;109(9):4089-4096.

Bei ONKODIN publiziert in Kooperation mit "Deutscher Ärzte-Verlag" (Publikation als Buch)
Deutscher Ärzte-Verlag  Deutscher Ärzte-Verlag
und in Kooperation mit "Studien-Allianz Leukämie"
Deutscher Ärzte-Verlag  Studien-Allianz Leukämien
Aktuelle Berichte vom 58th
ASH Annual Meeting 2016,
San Diego, Kalifornien, USA [Mehr]
2016 ASCO Annual Meeting - aktuelle Berichte. Dieser Service wird gefördert durch: